A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: An update
Cornu J.-N.,University Paris - Sud |
Ahyai S.,Universitatsklinikum Hamburg Eppendorf |
Bachmann A.,University of Basel |
De La Rosette J.,University of Amsterdam |
And 6 more authors.
European Urology | Year: 2015
Context A number of transurethral ablative techniques based on the use of innovative medical devices have been introduced in the recent past for the surgical treatment of benign prostatic obstruction (BPO). Objective To conduct a systematic review of the literature and a meta-analysis of available randomized controlled trials (RCTs), and to evaluate the efficacy and safety of transurethral ablative procedures for BPO. Evidence acquisition A systematic literature search was performed for all RCTs comparing any transurethral surgical technique for BPO to another between 1992 and 2013. Efficacy was evaluated after a minimum follow-up of 1 yr based on International Prostate Symptom Score, maximum flow rate, and postvoid residual volume. Efficacy at midterm follow-up, prostate volume, perioperative data, and short-term and long-term complications were also assessed. Data were analyzed using RevMan software. Evidence synthesis A total of 69 RCTs (8517 enrolled patients) were included. No significant difference was found in terms of short-term efficacy between bipolar transurethral resection of the prostate (B-TURP) and monopolar transurethral resection of the prostate (M-TURP). However, B-TURP was associated with a lower rate of perioperative complications. Better short-term efficacy outcomes, fewer immediate complications, and a shorter hospital stay were found after holmium laser enucleation of the prostate (HoLEP) compared with M-TURP. Compared with M-TURP, GreenLight photoselective vaporization of the prostate (PVP) was associated with a shorter hospital stay and fewer complications but no different short-term efficacy outcomes. Conclusions This meta-analysis shows that HoLEP is associated with more favorable outcomes than M-TURP in published RCTs. B-TURP and PVP have resulted in better perioperative outcomes without significant differences regarding efficacy parameters after short-term follow-up compared with M-TURP. Further studies are needed to provide long-term comparative data and head-to head comparisons of emerging techniques. Patient summary Bipolar transurethral resection of the prostate, photovaporization of the prostate, and holmium laser enucleation of the prostate have shown efficacy outcomes comparable with conventional techniques yet reduce the complication rate. The respective role of these new options in the surgical armamentarium needs to be refined to propose tailored surgical treatment for benign prostatic obstruction relief. © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Vincent M.W.,Tauranga Hospital |
Gilling P.J.,Tauranga Hospital
World Journal of Urology | Year: 2015
Introduction: Lower urinary tract symptoms (LUTS) are a common complaint and although can be adequately managed with medication, surgery remains the mainstay of treatment. Transurethral resection has been the reference ‘gold standard’, but due to its complications and issues with larger volume prostates, many alternatives have been developed and assessed. Holmium laser enucleation of the prostate (HoLEP) has shown excellent efficacy, durability and safety and has become an important alternative that has gained guideline approval.Results: HoLEP has been shown to have outcomes that are equivalent or better than TURP in both urodynamic measurements and symptom scores. Its outcomes have been proven to be durable and cost-effective. HoLEP has fewer and less serious complications when compared to the current reference standard, its use also allows earlier removal of catheter and hospital discharge. Appropriate mentoring reduces many of the issues associated with the steep learning curve, thus removing the main hurdle to its widespread adoption as the surgical treatment of choice for LUTS due to benign prostatic hyperplasia (BPH).Conclusions: HoLEP fulfils all of the requirements as an alternative/replacement for TURP and open prostatectomy, with equivalent outcomes and reduced complications. With improvements in the learning curve, it could now be considered the true gold standard surgical treatment for BPH. HoLEP has come of age. © 2014, Springer-Verlag Berlin Heidelberg.
Davis C.,Tauranga Hospital |
Boddington D.,Tauranga Hospital
Heart Lung and Circulation | Year: 2015
Introduction The cardiac effects of many illegal substances (cocaine, methadone) have previously been well described [1,2]. However the association between synthetic cannabis and cardiac arrest is less well documented. Here we describe an out-of-hospital cardiac arrest in a previously healthy 16-year-old female associated with the use of inhaled synthetic cannabis. Methods An electronic systematic search of online databases PubMed and Embase was performed using keywords, ''synthetic cannabis death'' and ''cardiac arrest''. Results In this case study a previously healthy 16-year-old had a cardiac arrest after synthetic cannabis use. Despite extensive investigations no other cause for her arrest was found. To the best of our knowledge there has been one previous case report of cardiac arrest following synthetic cannabis use in a 56-year-old man . Conclusions This case report augments the relationship between synthetic cannabis and cardiac arrest in the medical community. More awareness surrounding the risk of synthetic cannabinoids is warranted. © 2015 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ).
Singleton N.,Tauranga Hospital
The New Zealand medical journal | Year: 2013
It has been well demonstrated that Maori have the poorest health status of any ethnic group in New Zealand. The aim of this study was to determine whether there are any differences between Maori and non-Maori patients in the severity of their arthritis preoperatively and in their postoperative functional outcomes following primary total hip and knee arthroplasty surgery. Secondary objectives were to compare general and mental health scores and to determine whether the intervention rate for Maori arthroplasty patients is appropriate. We compared preoperative and postoperative (1 and 5 year) Oxford and WOMAC scores, general health (SF-12 PH) and mental health (SF-12 MH) scores in all public patients who underwent primary total hip and knee arthroplasty surgery in our region between 2005 and 2009. Maori patients are younger at the time of surgery, have higher ASA scores and worse preoperative function. They also have worse postoperative outcomes and smaller overall improvements following surgery when comparing their preoperative with postoperative scores. In terms of general health, Maori and non-Maori had similar SF-12 PH scores but worse SF-12 MH scores both pre- and postoperatively. Maori patients are younger, have worse general and mental health and worse preoperative function compared with non-Maori patients. Both absolute and differential scores show that Maori patients also have worse postoperative outcomes compared with non-Maori patients. These differences are likely clinically significant and ongoing education and effort is required in order to achieve earlier intervention rates and improve postoperative outcomes for Maori patients.
Chong J.,Tauranga Hospital |
Leung B.,Tauranga Hospital |
Poole P.,Tauranga Hospital
The Cochrane database of systematic reviews | Year: 2013
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is associated with cough, sputum production or dyspnoea and a reduction in lung function, quality of life and life expectancy. Apart from smoking cessation, there are no other treatments that slow lung function decline. Roflumilast and cilomilast are oral phosphodiesterase 4 (PDE4) inhibitors proposed to reduce the airway inflammation and bronchoconstriction seen in COPD.OBJECTIVES: To evaluate the efficacy and safety of oral PDE4 inhibitors in the management of stable COPD.SEARCH METHODS: We identified randomised controlled trials (RCTs) from the Cochrane Airways Group Specialised Register of trials (date of last search June 2013). We found other trials from web-based clinical trial registers.SELECTION CRITERIA: We included RCTs if they compared oral PDE4 inhibitors with placebo in people with COPD. We allowed co-administration of standard COPD therapy.DATA COLLECTION AND ANALYSIS: One review author extracted data and a second review author checked the data, before entry into The Cochrane Collaboration software program (RevMan version 5.2). We reported pooled data as mean differences (MD), standardised mean differences (SMD) or odds ratios (OR).MAIN RESULTS: Twenty-nine separate RCTs studying roflumilast (15 trials, 12,654 patients) or cilomilast (14 trials, 6457 patients) met the inclusion criteria, with a duration between six weeks and one year. These included people across international study centres with moderate to very severe COPD (GOLD grades II-IV), with a mean age of 64 years.Treatment with a PDE4 inhibitor was associated with a significant improvement in forced expiratory volume in one second (FEV1) over the trial period compared with placebo (MD 45.60 mL; 95% confidence interval (CI) 39.45 to 51.75, 22 trials with 15,670 participants, moderate quality evidence due to moderate levels of heterogeneity and risk of reporting bias). There were small improvements in quality of life (St George's Respiratory Questionnaire MD -1.04; 95% CI -1.66 to -0.41, 10 trials with 7618 participants, moderate quality evidence due to moderate levels of heterogeneity and risk of reporting bias) and COPD-related symptoms, but no change in exercise tolerance. Treatment with a PDE4 inhibitor was associated with a reduced likelihood of COPD exacerbation (OR 0.77; 95% CI 0.71 to 0.83, high quality evidence). For every 100 people treated with PDE4 inhibitors, six more remained exacerbation-free during the study period compared with placebo (number needed to treat for an additional beneficial effect (NNTB) 20; 95% CI 16 to 27). More participants in the treatment groups experienced non-serious adverse events compared with controls, particularly gastrointestinal symptoms and headache. Roflumilast in particular was associated with weight loss during the trial period and an increase in insomnia and depressive mood symptoms. Participants treated with PDE4 inhibitors were also more likely to withdraw from the trials because of adverse effects; on average 24% in the treatment groups withdrew compared with 19% in the control groups.AUTHORS' CONCLUSIONS: In people with COPD, PDE4 inhibitors offered benefit over placebo in improving lung function and reducing the likelihood of exacerbations; however, they had little impact on quality of life or symptoms. Gastrointestinal adverse effects and weight loss were common, and safety data submitted to the US Food and Drug Administration (FDA) have raised concerns over psychiatric adverse events with roflumilast. The optimum place of PDE4 inhibitors in COPD management therefore remains to be defined. Longer-term trials are needed to determine whether or not PDE4 inhibitors modify FEV1 decline, hospitalisation or mortality in COPD.
Kahokehr A.,Tauranga Hospital |
Gilling P.J.,Tauranga Hospital
Current Opinion in Urology | Year: 2014
PURPOSE OF REVIEW: Endoscopic enucleation of the prostate is the most advanced form of surgical management of benign prostate hyperplasia. The purpose of this review is to update the reader on various modalities currently in use, and in trial, for endoscopic enucleation. RECENT FINDINGS: A recent paradigm shift has occurred for the proponents of electrosurgery technology to utilizes the advantages offered by laser enucleation with interest in bipolar enucleation. Holmium laser enucleation still has the greatest randomized evidence with the longest follow-up among all the various lasers used to perform enucleation. SUMMARY: Randomized trials with longer follow-up are required to demonstrate whether nonholmium types of energy really have advantages in enucleation (speed, ease of use and hemostasis) and durability (decade plus) as compared to the holmium laser. © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Chancellor A.M.,Tauranga Hospital
Practical Neurology | Year: 2013
A sporadic seasonal neurotoxic food poisoning, unique to northern parts of New Zealand, especially The Bay of Plenty, has recurred-with implications for our primary produce industry, as well as human health.
Van Rij S.,Tauranga Hospital |
Gilling P.J.,Tauranga Hospital
Current Urology Reports | Year: 2012
In this review article, we assess why holmium laser enucleation of the prostate (HoLEP) has become an important treatment modality for benign prostatic hypertrophy (BPH). Meta-analysis comparing HoLEP with both open prostatectomy (OP) and transurethral resection of prostate (TURP) shows TURP to be as effective with less morbidity. More recently, HoLEP has long-term durability data confirming a very low reoperation rate. This article investigates how previous hurdles to the widespread uptake of HoLEP have been overcome. Recent literature shows that the learning curve is actually similar to many other current urological procedures, and that the efficiency of HoLEP is equal to that of other surgical procedures. HoLEP is also beneficial in the growing population of men on anticoagulation who require treatment for BPH. Finally, HoLEP is the only laser treatment for BPH with level 1 evidence and endorsement in both the American Urological Association (AUA) and European Association of Urology (EAU) guidelines. © 2012 Springer Science+Business Media, LLC.
Bade K.,Tauranga Hospital |
Hoogerbrug J.,Tauranga Hospital
Journal of Surgical Education | Year: 2015
Background Resource scarcity continues to be an important problem in modern surgical practice. Studies in North America and Europe have found that medical professionals have limited understanding of the costs of medical care. No cost awareness studies have been undertaken in Australasia or specifically focusing on the surgical team. This study determined the cost of a range of commonly used diagnostic tests, procedures, and hospital resources associated with care of the surgical patient. The surgical teams' awareness of these costs was then assessed in a multicenter cross-sectional survey. Methods In total, 14 general surgical consultants, 14 registrars, and 25 house officers working in three New Zealand hospitals were asked to estimate the costs of 14 items commonly associated with patient care. Cost estimations were considered correct if within 25% plus or minus of the actual cost. Accuracy was assessed by calculating the median, mean, and absolute percentage discrepancy. Results A total of 57 surveys were completed. Of which, four were incomplete and were not included in the analysis. Cost awareness was generally poor, and members of the surgical team were rarely able to estimate the costs to within 25%. The mean absolute percentage error was 0.87 (95% CI: 0.58-1.18) and underestimates were most common. There was no significant difference in estimate accuracy between consultants, registrars, or house officers, or between consultants working in both public/private practice compared with those working in public practice alone. Conclusion There is poor awareness of surgical costs among consultant surgeons, registrars, and junior physicians working in Australasia. © 2014 Association of Program Directors in Surgery.
Wilson L.C.,Tauranga Hospital |
Gilling P.J.,Tauranga Hospital
BJU International | Year: 2011
OBJECTIVES To review the urological literature regarding the management of Post-Prostatectomy Incontinence (PPUI) METHODS A Pubmed literature search was performed RESULTS The definition of Post-Prostatectomy Incontinence varied widely The artificial urinary sphincter has proven efficacy and durability Newer devices, in particular the AdVance sling, lack quality studies despite its apparent popularity CONCLUSION Currently there is insufficient evidence to determine whether newer devices approach the efficacy and durability of the artificial urinary sphincter © 2011 BJU INTERNATIONAL.